Although the short-term benefit of isoniazid prophylaxis in patients coinfected with human immunodeficiency virus (HIV) and tuberculosis has been shown, long-term benefits are unknown.
Historical cohort study in an acquired immunodeficiency syndrome unit at a tertiary referral hospital.
A sample of 121 HIV-infected patients with positive results on a purified protein derivative test were followed up for development of active tuberculosis and survival.
Patients who received isoniazid prophylaxis were compared with patients who did not receive prophylaxis.
Of the 121 patients examined, 29 (24%) completed a 9-to 12-month course of isoniazid prophylaxis (median follow-up, 89 months), and 92 (76%) did not receive the drug (median follow-up, 60 months).
Active tuberculosis developed in 46 patients (38%). The incidence of tuberculosis was higher among patients with no prophylaxis (9.4 per 100 patient-years) than among patients with isoniazid prophylaxis (1.6 per 100 patient-years) (P=006).
Risk for development of tuberculosis was associated with the absence of isoniazid prophylaxis (relative risk [RR], 6.55 ; 95% confidence interval [CI], 2.02-21.19).
Death during the period of study was more frequent in patients who did not receive isoniazid (50/92 or 54%) than in patients who received isoniazid (7/29 or 24%) (P=008). (...)
Mots-clés Pascal : SIDA, Virose, Infection, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Association, Tuberculose, Mycobactériose, Bactériose, Etude cohorte, Prévention, Isoniazide, Evaluation, Long terme, Mycobacterium tuberculosis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bactérie, Survie, Homme, Immunopathologie, Immunodéficit, Organisation santé, Antituberculeux
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Association, Tuberculosis, Mycobacterial infection, Bacteriosis, Cohort study, Prevention, Isoniazid, Evaluation, Long term, Mycobacterium tuberculosis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bacteria, Survival, Human, Immunopathology, Immune deficiency, Public health organization, Antituberculous agent
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0429068
Code Inist : 002B02S07. Création : 19/12/1997.